厦泰生物（Cytek Biosciences）总部位于美国硅谷，是纳斯达克上市公司。截止目前厦泰在美国硅谷、中国北京、中国上海、中国无锡、荷兰阿姆斯特丹、日本东京设有分支机构。厦泰致力于发展新一代细胞分析解决方案，通过更高维度的高品质数据帮助科研人员深入洞悉生命科学。我们将持续推进生命科学与肿瘤学研究发展作为公司坚定不移的使命，为此我们荣幸地推出Cytek全光谱流式技术，助力科研人员百尺竿头更进一步。
厦泰公司产品凭借卓越的技术性能风靡世界*级研究机构和制药公司。作为一家不断成长的创新型公司，我们一直在寻求充满活力且受过良好教育的专业人士。如果您希望在专业和个人能力方面进一步拓展，欢迎加入我们团队。
包容性和多样性是厦泰的核心价值观，我们高度重视每一个员工的创意与观点。厦泰团队代表了许多不同的文化、背景和观点。作为一家有责任的企业，我们力求保持高水平的道德标准，始终秉承诚实、忠诚、透明的企业文化。我们将致力于向全球科研人员提供最诚挚的服务。
Cytek Biosciences is a high-tech enterprise engaged in the development, production, sales and after-sales service of flow cytometers and supporting solutions. It is headquartered in Silicon Valley, USA, and has offices in Shanghai and Wuxi China, as well as in Tokyo, Japan, and Amsterdam, the Netherlands. Cytek was listed on NASDAQ in the United States in 2021, marking a new chapter in the company's development into a standardized group.
Cytek Biosciences is committed to providing powerful solutions that enable scientists to rapidly and efficiently obtain deep biological insights through high quality, high parametric datasets. We are on a mission to advance cancer and cell biology research using a powerful cell analysis technique called full spectrum flow cytometry.
We have successively developed and launched DxP AthenaTM traditional flow cytometry analyzers, CytekTM Aurora series full-spectrum flow cytometry analyzers, CytekTM Northern Lights series and other full-spectrum flow cytometry analyzers, related diagnostic reagents and other products, our full-spectrum flow cytometry The cytometer is hailed as a revolutionary and innovative product in the industry, and has been sold to top scientific research institutions, pharmaceutical companies and CRO companies on four continents around the world.
Cytek Biosciences is a young and energetic foreign-funded enterprise. The company is inseparable from the talents with innovative ability, hard work spirit and teamwork spirit. Welcome to join us with the pursuit of dreams and challenges. The company provides you with broad development platform, perfect welfare and competitive treatment. We look forward to working together with you to create a better future.